Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2016 Financial Results on Monday, August 1, 2016
July 29 2016 - 8:30AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
renal disease, today announced that it will host a conference call
and webcast on Monday, August 1, 2016 at 8:30 a.m. ET to discuss
its second quarter 2016 financial results and provide a company
update.
To participate in the conference call, please dial
1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to
conference ID: 58777481. The call will be webcast live and
accessible through the Investors section of the company’s website
at www.keryx.com for a period of 15 days after the call.
About Keryx Biopharmaceuticals,
Inc. Keryx Biopharmaceuticals, with headquarters in
Boston, is focused on bringing innovative medicines to people with
renal disease. In December 2014, the company launched its first
FDA-approved medicine, Auryxia® (ferric citrate) in the United
States. In January 2014, ferric citrate was approved for use
in Japan, where it is being marketed as Riona® by Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In
September 2015, the European Commission granted European market
authorization for Fexeric® (ferric citrate coordination complex).
For more information about Keryx, please visit www.keryx.com.
Keryx Biopharmaceuticals Contact:
Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024